MedTrace Logo

Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis

NCT00222222 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2012-02-16

No results posted yet for this study

Summary

Aims of the study were to find vascular markers of inflammation and endothelial damage during the course of severe sepsis in septic patients and the effects of treatment with anti-inflammatory medication (such as Drotregocin alfa (activated)). Another aim is to find new markers and gene polymorphisms for prognosis and mortality of patients with severe sepsis. The hypothesis is that higher plasma concentrations of certain markers in septic patients are associated with a higher mortality rate.

Conditions

Interventions

PROCEDURE

vein puncture

comparison of different inflammatory markers in the blood of septic patients

Sponsors & Collaborators

  • Universitätsmedizin Mannheim

    lead OTHER

Principal Investigators

  • Ursula Hoffmann, MD · First Department of Medicine, University Medical Centre Mannheim

  • Michael Behnes, MD · University Medical Centre Mannheim

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Germany

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222222 on ClinicalTrials.gov